ZHANG Yingxuan,CHEN Wenli,CHEN Hongyu,et al.Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):291-295.
ZHANG Yingxuan,CHEN Wenli,CHEN Hongyu,et al.Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(S1):291-295. DOI: 10.16306/j.1008-861x.2022.S1.059.
Research progress of polypeptide polymerized nanodrugs in tumor targeted therapy
Due to the characteristics of tumor microenvironment and biological barrier, chemotherapy, immunity, traditional Chinese medicine and other drugs are difficult to penetrate and destroy tumor genetic material. Polypeptide polymerized nanodrugs have the characteristics of easy assembly, degradability and targeting, and the delivery system mediated by polypeptide polymerized nanodrugs has become the main research direction of tumor targeted drug release. This paper summarizes the recent progress of polypeptide nanodrugs that use multi-target combination and response of nanodrug delivery system, to tumor targeted release, improve the precise penetration curative efficacy of anti-tumor drugs such as chemotherapy, immunity and traditional Chinese medicine, and reduce oral absorption insoluble, toxic and side effects. This field will also become the main development direction of antitumor drug research in the future.
KUMAR R, SHIN W S, SUNWOO K, et al. Small conjugate-based theranostic agents: an encouraging approach for cancer therapy[J]. Chem Soc Rev, 2015, 44(19): 6670-6683.
DREIFUSS T, BETZER O, SHILO M, et al. A challenge for theranostics: is the optimal particle for therapy also optimal for diagnostics? [J]. Nanoscale, 2015, 7(37): 15175-15184.
ZHU H J, FANG Y, MIAO Q Q, et al. Regulating near-infrared photodynamic properties of semiconducting polymer nanotheranostics for optimized cancer therapy[J]. ACS Nano, 2017, 11(9): 8998-9009.
SNEIDER A, DYKE D V, PALIWAL S,et al. Remotely triggered nano-theranostics for cancer applications[J]. Nanotheranostics, 2017, 1(1): 1-22.
HOFMANN S, BELLMANN-SICKERT K, BECK-SICKINGER A G. Chemical modification of neuropeptide Y for human Y1 receptor targeting in health and disease[J]. Biol Chem, 2019, 400(3): 299-311.
VEGGIANI G, SIDHU S S. Peptides meet ubiquitin: Simple interactions regulating complex cell signaling[J]. Peptide Science, 2018, 111(1): e24091.
GHADIRI M R,GRANJA J R,MILLIGAN R A,et al. Self-assembling organic nanotubes based on a cyclic peptide architecture[J]. Nat, 1993, 366(6453): 324-327.
DE GROOT N S,PARELLA T,AVILES F X, et al. Ile-phe dipeptide self-assembly: clues to amyloid formation[J]. Biophys J,2007,92(5):1732-1741.
SAKET A,VIKAS P,VANDANA S. RGD Peptide as a Targeting Moiety for Theranostic Purpose: An Update Study[J]. Int J Pept Res Ther, 2018, 25: 49-65.
BERTRAND N, WU J, XU X, et al. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology[J]. Adv Drug Delivery Rev, 2014, 66: 2-25.
STONE O A,EL-BROLOSY M,WILHELM K,et al. Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells[J]. Nat Commun,2018,9(1):4077.
WANG Z,NIU G,CHEN X. Polymeric materials for theranostic applications.[J]. Pharm Res,2014,31(6):1358-1376.
HUANG G,KHEMTONG C,BEY E A,et al. Theranostic Polymeric Micelles for Cancer Imaging and Therapy[J]. Nanostruct Sci Technol, 2012, 12: 257-276.
ADAMS M L, LAVASANIFAR A,KWON G S. Amphiphilic block copolymers for drug delivery[J]. J Pharm Sci, 2003, 92(7): 1343-1355.
MUNTIMADUGU E, KOMMINENI N,KHAN W. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvir-onment for Cancer Therapy [J]. Pharmacol Res, 2017, 126: 109-122.
SHI J,KANTOFF P W,WOOSTER R,et al.Cancer nanomedicine: progress, challenges and opportunities[J]. Nat Rev Cancer, 2017, 17(1): 20-37.
QIN Y,CHEN H,ZHANG Q,et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals[J]. Int J Pharm,2011, 420(2): 304-312.
WAN G Y, CHENG Y Y, SONG J,et al. Nucleus-targeting near-infrared nanoparticles based on TAT peptide-conjugated IR780 for photo-chemotherapy of breast cancer[J]. Chem Eng J, 2020, 380: 122458.
GUO F, WU J, WU W, et al. PEGylated self-assembled enzyme-responsive nanoparticles for effective targeted therapy against lung tumors[J]. J Nanobiotechnology, 2018, 16(1): 57.
WANG Y, XUAN J, ZHAO W, et al. Smart and Selective Cancer-Killing Peptides with Cell Penetrating Sequence and Dual-Targeting Mechanism[J]. Colloids Surf, 2019, 586: 124185.
WANG J, LI N, CAO L, et al. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells[J]. J Mater Chem B, 2020, 8(6): 1157-1170.
SHI J, LIU S, YU Y, et al. RGD peptide-decorated micelles assembled from polymer-paclitaxel conjugates towards gastric cancer therapy[J]. Colloids Surf B, 2019, 180: 58-67.
GESSNER I, NEUNDORF I. Nanoparticles Modified with Cell-Penetrating Peptides: Conjugation Mechanisms, Physicochemical Properties, and Application in Cancer Diagnosis and Therapy[J]. Int J Mol Sci, 2020, 21(7): 2536.
SHI X L,ZHU K Y, YE Z D, et al. VCP/p97 targets the nuclear export and degradation of p27Kip1 during G1to S phase transition [J]. FASEB J, 2020, 34(4):5 193-5207.
SONG W,SHEN L,WANG Y,et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap[J]. Nat Commun, 2018, 9(1): 2237.
GOODWIN T J,SHEN L,HU M,et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival[J]. Biomaterials, 2017, 141: 260-271.
MOON Y W,HAJJAR J, HWU P,et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer[J]. J Immunother Cancer, 2015, 3: 51.
LU K,HE C,GUO N,et al. Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy[J]. J Am Chem Soc, 2016, 138(10): 12502.
KUAI R, OCHYL L J,BAHJAT K S,et al. Designer vaccine nanodiscs for personalized cancer immunotherapy[J]. Nat Mater,2017, 16: 489-496.
ROSS H,BONOMI P,LANGER C,et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonave pts with advanced NSCLC and poor performance status (PS2)[J]. J Clin Oncol, 2006, 24(18 suppl): 7039-7039.
PAZ-ARES L, ROSS H,O’BRIEN M,et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer[J]. Br J Cancer, 2008, 98(10): 1608-1613.
HE C, DUAN X,GUO N,et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy[J]. Nature Communications, 2016, 7: 12499.
LI C,CAI G,SONG D,et al. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer[J]. Biomater Sci,2019, 7(9): 3627-3639.
HAFSI M,PREVERAL S, HOOG C,et al. RGD-functionalized magnetosomes are efficient tumor radioenhancers for X-rays and protons[J]. Nanomedicine, 2020, 23: 102084.
ZHEN Z,TANG W,WANG M,et al. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control[J]. Nano Letters, 2017, 17: 862-869.
YAN J,WU Q,ZHAO Z,et al. Light-assisted hierarchical intratumoral penetration and programmed antitumor therapy based on tumor microenvironment (TME)-amendatory and self-adaptive polymeric nanoclusters[J]. Biomaterials, 2020, 255: 120166.